MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Additional Positive Data from Phase 1 MAD Study of DA-1726 in Obesity ...

Available webcasts will be accessible on Skye's website.

Newly recognized issues, including extreme fatigue with excessive weight reduction, bone loss, and abdominal pain, point to ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

The findings add to other research showing a lower risk of obesity-related cancers in patients taking GLP-1 drugs, a class of ...

GLP-1 receptor agonists may reduce risk for obesity-related cancers among people with diabetes compared with dipeptidyl ...

The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off ...

In the fourth part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, explains how GLP-1 therapies’ success can influence future investment ...

A look at new technologies that allow an “Amazon experience” for pharmacists waiting for life sciences shipments.

Home Online Features What You Need to Know About GLP-1 Weight-Loss Drugs Now That the FDA Says the Shortage Is Over Community ...